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ABSTRACT 
     The simple diamine diaminoethane (ethylenediamine, EDA) has been shown to 
activate GABA receptors in the central and peripheral nervous systems, partly by a 
direct action and partly by releasing endogenous GABA. These effects have been 
shown to be produced by the complexation of EDA with bicarbonate to form a 
carbamate. The present work has compared EDA, GABA and β-alanine responses in 
rat CA1 neurons using extracellular and intracellular recordings, as well as 
neocortical evoked potentials in vivo. Superfusion of GABA onto hippocampal slices 
produced depolarisation and a decrease of field epsps, both effects fading rapidly, 
but showing sensitivity to blockade by bicuculline. EDA produced an initial 
hyperpolarisation and increase of extracellular field epsp size with no fade and only 
partial sensitivity to bicuculline, with subsequent depolarisation, while β-alanine 
produces a much larger underlying hyperpolarisation and increase in fepsps, 
followed by depolarisation and inhibition of fepsps. The responses to β-alanine, but 
not GABA or EDA, were blocked by strychnine. In vivo experiments, recording 
somatosensory evoked potentials, confirmed that EDA produced an  initial increase 
followed by depression, and that this effect was not fully blocked by bicuculline. 
Overall the results indicate that EDA has actions in addition to the activation of GABA 
receptors. These actions are not attributable to activation of β-alanine-sensitive 
glycine receptors, but may involve the activation of sites sensitive to adipic acid, 
which is structurally equivalent to the dicarbamate of EDA. The results emphasise 
the complex pharmacology of simple amines in bicarbonate-containing solutions. 
 
Key-words:  Ethylenediamine; 1,2-diaminoethane; GABA; bicuculline; kynurenic 
acid; hippocampus; cortical evoked potentials 
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1. INTRODUCTION 
     Ethylenediamine (1,2-diaminoethane, EDA) is used as a complexing and 
solubilising agent in preparations such aminophylline, which is a complex of EDA and 
theophylline. When aminophylline was applied by microiontophoresis to 
spontaneously firing neurones in vivo (Stone and Perkins, 1979) it produced a 
depression of neuronal firing, leading to the realisation that the inhibition was entirely 
attributable to the EDA, not the theophylline component of the complex (Perkins and 
Stone, 1980,1982a; Perkins et al., 1981). This conclusion was confirmed by others 
studying neuronal activity in the hippocampus (Blaxter and Cottrell 1985), cerebellum 
and invertebrate CNS (Bokisch et al., 1984). 
   Both EDA and GABA showed the same reversal potential, the depressant activity 
was blocked by bicuculline (Perkins et al., 1981; Perkins and Stone, 1982a) and 
potentiated by benzodiazepines (Bokisch et al., 1984). Neurochemical analyses 
showed that EDA could be transported into GABA-containing synaptic terminals, 
provoking the selective release of GABA but not dopamine (Lloyd et al., 1982a,b; 
Kerr and Ong, 1982, 1987; Sarthy, 1983). Overall, EDA was a GABA-mimetic, acting 
partly indirectly by GABA release (either by uptake and displacement of synaptic 
GABA or by promoting the exchange of GABA for EDA) and partly by direct 
activation of GABAA receptors (Morgan and Stone, 1982; Davies et al., 1982). Later 
work indicated that EDA can activate GABA receptors in smooth muscle (Ong and 
Kerr, 1987; Barbier et al, 1989; Maggi et al., 1989; Chaudhuri and Ganguly, 1994, 
Begg et al., 2002), partly via endogenous GABA release (Kerr and Ong, 1984; Erdo 
et al., 1986; Mckay and Krantis, 1991).  
     In order to explain this neuronal inhibition by a simple amine lacking any oxygen-
containing functional group, it was proposed that the positively charged amine groups 
 3
of EDA might interact with bicarbonate ions in solution (Stone and Perkins, 1984) to 
generate an aliphatic structure resembling GABA. The existence of the postulated 
complex was subsequently confirmed and identified as EDA monocarbamate (Curtis 
and Malik, 1984; Kerr and Ong, 1987), which reproduced the activity of EDA. 
Analogues with longer or branched structures are much less effective as GABA-
mimetics (Perkins and Stone 1982a). 
     The similarity between EDA and GABA pharmacology extended to the ability of 
nipecotic acid to inhibit EDA uptake in brain slices (Lloyd et al., 1982b) and the ability 
of depolarising stimuli to release EDA in a calcium-dependent fashion.  
     Overall, these results indicated that EDA might make a valuable tool to explore 
aspects of GABA synaptic pharmacology, promoting the effects of endogenous 
GABA released from synaptic terminals. However, there remain several unanswered 
questions. For example, GABA acts on CA1 apical dendrites with a hyperpolarisation 
that is not blocked by bicuculline (Alger and Nicoll, 1982) although it is still mediated 
via GABAA and not GABAB receptors. Therefore, the present study was designed to 
re-examine the pharmacology of EDA under the controllable conditions of 
hippocampal slices. In addition, it was of interest to examine the effects of EDA in 
vivo, where the intercellular milieu is more complex and adaptive than under in vitro 
conditions.  
 
 
2. MATERIALS AND METHODS 
2.1 General 
   All procedures performed in this work were in accordance with the regulations and 
recommendations of the Animals (Scientific Procedures) Act, 1986 of the United 
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Kingdom Home Office. Hippocampal slices were prepared as described previously 
(see Stone, 2007; Ferguson and Stone, 2008). Briefly, male Wistar rats weighing 
100-150g were killed by administering an overdose of urethane (10ml/kg body weight 
i.p., as a 25% solution in water) followed by cervical dislocation. The brain was 
rapidly removed into ice-cold artificial cerebrospinal fluid (aCSF) of composition: (in 
mM) NaCl 115; KH2PO4  2.2; KCl  2; MgSO4  1.2; NaHCO3 25; CaCl2 2.5; D-
glucose 10, gassed with 5%CO2 in oxygen. The hippocampi were chopped into 
450µm transverse slices using a McIlwain tissue chopper. The slices were 
preincubated at room temperature for at least 1 hour in a water-saturated 
atmosphere of 5%CO2 in O2 before individual slices were transferred to a 1 ml 
capacity superfusion chamber for recording. 
     For extracellular recording, submerged slices were superfused with aCSF at 28-
30°C and a flow rate of 3-4 ml/min. The Schaffer collaterals and commissural 
afferents to the CA1 region were stimulated using a concentric bipolar electrode 
(Harvard Apparatus, Edenbridge, UK) positioned in the stratum radiatum, (0.1 Hz 
stimulation using a pulse duration of 50-300µs. The stimulating electrode tip was 
located immediately internal to the stratum pyramidale at the border between the 
CA1 and CA2 regions. For antidromically-evoked potentials, the stimulating electrode 
was placed in contact with the alvear white matter containing the axons of the 
pyramidal neurons. Recording electrodes were constructed from fibre-containing 
borosilicate glass capillary tubing (Harvard Apparatus, Edenbridge, Kent, UK), with 
the tips broken back under microscopic control to 2-4µM, DC resistance 
approximately 5MΩ. These electrodes were filled with a solution of 1M NaCl. The 
recording electrode tip was placed either in the stratum pyramidale (for population 
spike recordings) or internal to the CA1 pyramidal cell layer at the point of maximum 
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epsp amplitude. The potentials were amplified and captured on a micro1401 interface 
(CED, Cambridge Electronic Design, Cambridge, UK) for storage on computer and 
subsequent analysis using Signal software (CED, Cambridge, UK).  The amplitude of 
population spikes was taken as the potential difference between the negative and 
positive peaks of the potential. The negative slope of the epsp was taken as the 
gradient of the line of best fit of all sampled points between approx. 25% and 75% 
after the start of the negative slope. The epsp amplitude was taken as the potential 
difference between the negative peak of the epsp and the pre-stimulus baseline.  
   Intracellular recordings were made as described previously (Stone, 2007), using 
sharp electrodes pulled from fibre-containing glass capillary tubing (Clark 
Electromedical, Reading, UK, and Harvard Apparatus, Edenbridge, UK) using a 
vertical Narashige puller. The electrodes were filled with 1M potassium acetate, and 
had tip resistances of 90-120 MΩ. Potentials were amplified via an Axoclamp-2 
system or Neurolog DC amplifier in bridge balance mode, with a filter bandwidth 
between DC and 500Hz to reduce higher frequency components of epsp recordings. 
Following penetration, cells were allowed to reach a maximum resting potential and 
then left for 30 min before the addition of compounds into the superfusion line. Cells 
were only used if they exhibited stable resting potentials of at least –60mV. Neuronal 
excitability was tested by applying intracellular depolarising current pulses between 
0.05 and 1.0nA amplitude. Input resistance was monitored using 0.05 to 1.0nA 
hyperpolarizing pulses. Responses were digitised at 20kHz via a CED (Cambridge 
Electronic Design, Cambridge, UK) micro1401 interface and stored on computer for 
later analysis using the Signal programme (CED). Only one cell was studied in each 
slice, to preclude the possibility that drug superfusion might alter the responsiveness 
of subsequent neurons in the same slice.  
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 2.2  In vivo electrophysiology 
   The in vivo work was approved by the local Ethics Committee for the use of 
animals. Male Sprague Dawley rats weighing 200-320g were housed and maintained 
at the animal care facility of the university’s veterinary hospital according to the 
standards of the local ethics committee. The rats had free access to food and water 
with a 12 hour light/dark cycle.  The experimental procedures we used for recording 
somatosensory evoked potentials (SEPs) have been described in previous reports 
(Addae et al., 2000, 2007). Briefly, following anesthesia with urethane (1.5-1.7 g/kg) 
the rats were mounted in a stereotaxic frame and the body temperature maintained 
at 37oC by means of a heating blanket and a rectal thermistor. A burr hole, 3-4 mm in 
diameter, was made to expose the cortical area that represents the forepaw and the 
dura mater and arachnoid mater were removed in this area to allow recording of the 
SEPs and application of drugs via a cortical cup. The contralateral forepaw was 
stimulated at 0.5 Hz using needle electrodes inserted into the skin of the forepaw, 
and the SEPs were recorded at 0.8-1.2mm below the cortical surface with a glass 
microelectrode filled with 3M NaCl (resistance of approximately 5 MΩ).  Individual 
SEPs were recorded using a CEDmicro1401 computer interface and Signal software 
(Cambridge Electronic Design, UK). Changes in SEP amplitude were calculated as a 
percentage of the mean baseline value. Following application of drugs the cortex was 
washed by continuous superfusion of pre-gassed (95%O2/ 5%CO2 ) artificial 
cerebrospinal fluid (aCSF) with the following composition (in mM): NaCl 115.0; KCl 
2.0; KH2PO4 2.2; NaHCO3 25.0; D-Glucose 10; MgSO4 1.2 and CaCl2 2.5. 2.5. EDA 
and bicuculline methobromide were dissolved in the aCSF, although when EDA was 
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being applied at high concentrations it was dissolved in aCSF with reduced 
concentrations of NaCl to maintain isotonicity of the solution. 
     Data are expressed as mean ± S.E.M.. Statistical comparisons of two data sets 
were made with an unpaired Student’s t-test. Comparisons of multiple data sets were 
made using ANOVA. 
 
2.3  Statistics 
    Data are presented throughout as mean ± standard error. Baseline values were 
obtained from a stable 10min period of evoked potential size prior to the addition of 
any drugs, with the first of those potentials being defined as 100%. This allowed the 
10min pre-drug period to provide an indication of baseline variance. For statistical 
comparisons between two groups, unpaired, two-tailed t-tests were used, but where 
two or more data sets were compared with a common control, an analysis of 
variance (ANOVA) was performed, followed by Dunnett’s test for comparisons with a 
common control, or the Bonferroni test for selected pairs of columns as appropriate. 
All analyses were conducted using Instat software. 
 
2.4  Sources 
Glutamate, 4-aminobutyric acid (GABA), glycine, β-alanine, adipic acid, α-amino-
adipic acid, ethylenediamine dihydrochloride (EDA), strychnine and nipecotic acid, 
were obtained from Sigma-Aldrich Chemical Company, Poole, UK.  
(-)bicuculline methobromide (BIC), 3-((R)-2-carboxypiperazin-4-yl)-propyl-1-
phosphonic acid (CPP), (3-aminopropyl)(diethoxymethyl)phosphinic acid 
(CGP35348) and gabazine were obtained from Tocris Chemicals, Bristol, UK. 
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 3.  RESULTS 
3.1  Responses to EDA and GABA 
     The main response to EDA was a reduction in the size of fepsps (Fig. 1A,B). The 
time course of responses is illustrated by the family of curves obtained in response to 
maintained (10min) applications of EDA such that responses reached a plateau 
(Fig.1A). The corresponding log concentration-response curves are constructed in 
Fig.1C. When perfusion with EDA was maintained until this plateau of depression, a 
significant effect could be seen at a concentration as low as 50µM (Fig. 1B,C). None 
of these responses to EDA were associated with any changes in the size of the 
axonal volley (Fig.1B). In an initial series of 16 slices tested with EDA at 1mM or 
above, 4 slices showed a depression of fepsps which was preceded by a small 
increase in size which reached 120.9 ± 2.2% of the initial baseline (n = 4, significantly 
different from baseline, P = 0.006), and was not clearly related to concentration. 
     At concentrations below approximately 1mM, the effects of EDA were normally 
fully reversible, with potential size returning to levels not significantly different from 
the initial baseline values (Fig. 1A). At concentrations of 1 mM or above, a proportion 
of slices showed a long-lasting depression of fepsp size. Overall, of the initial group 
of 16 slices perfused with EDA alone at 1mM or above, 12 showed a fully reversible 
depressant effect of EDA on fepsps, while 4 showed persistent depression after 
recovering only partially towards baseline levels. This long-lasting depression was 
even more evident when slices were perfused for a shorter period of 5min (Fig. 1D).  
     For comparison, GABA was superfused over slices at a range of concentrations 
similar to those used for EDA (Fig. 1C). The responses obtained were of a broadly 
similar magnitude and time course to those seen with EDA, although there were no 
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instances of initial increases in fepsp size, and all responses returned to the baseline 
levels, with no maintained depression. Indeed, when applied at concentrations of 
500µM or above for 10min, the fepsp size reached a peak of depression after about 
1min, before this effect began to fade, starting to recover towards baseline values 
during the continued presence of GABA. In these cases, for the purpose of 
constructing the concentration-response curve in Fig. 1C, the amplitude of the 
response was taken as the maximum extent of the depression.  
 
3.2  GABA receptor blockade 
     In order to examine the pharmacology of these responses, EDA was applied at a 
concentration of 1mM for periods of 2 min, once every 10-15 min. This protocol 
allowed the establishment of two consistent control responses, followed by the 
application of a potential modulator and then recovery of the original EDA response. 
The results were discarded from any slices in which the EDA response did not 
recover to within 10% of its initial value.  
      The application of bicuculline methobromide to slices tends to result in the 
development of multiple population spikes in the recordings of fepsp, together with 
the occurrence of spontaneous epileptiform bursting. These experiments were 
therefore conducted in slices in which a cut was made between the CA3 and CA1 
regions, approximately at the border between CA2 and CA3. While this did not 
completely prevent signs of hyperexcitability, the changes seen did not interfere with 
the overall behaviour of the slices, or affect their eventual recovery. 
     Slices were superfused with bicuculline for 10 min before the addition of 1mM 
EDA for 2 min, with continued perfusion of bicuculline during subsequent applications 
of EDA. The application of bicuculline at a concentration of 20µM produced a slowly 
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developing reduction in the size of fepsp responses to EDA, with a maximal reduction 
after approximately 30 min of bicuculline (Fig. 2A), and with no changes of axonal 
volley amplitude (Fig. 2B). A higher concentration of 100µM bicuculline antagonised 
EDA more rapidly but did not produce any greater maximal degree of antagonism 
(Fig. 2C).  
     Since bicuculline is known to affect some receptors and channels in addition to 
those for GABA, experiments were also performed using gabazine, a highly selective 
antagonist at GABAA receptors. In these cases, a similar, partial antagonism of EDA 
was seen when gabazine (20µM) was used, a concentration known to block GABAA 
receptors (Lindquist et al., 2005) (Fig. 2C). A higher concentration of 100µM did not 
produce a significantly greater reduction of the EDA response (Fig. 2C). 
      In contrast to these results, bicuculline at 20µM produced a complete blockade of 
the responses to GABA (1mM; data not shown). On the other hand, neither 
strychnine (10 or 100µM) (Fig. 2C) nor the GABAB receptor antagonist CGP35348 
(100µM; data not shown) were able to produce any significant reduction in the size of 
responses to EDA.  
     Similarly, perfusion with neither bicuculline nor strychnine produced any change in 
the size of the initial increase of fepsp size. On those slices showing this aspect of 
the response, the fepsp size was increased by 16.43 ± 1.20% with EDA alone (n = 
3); 16.87 ± 2.89% with EDA and bicuculline (n = 3); and 16.77 ± 2.5% with EDA and 
strychnine (n = 3). These increases were not significantly different (ANOVA (F(2,8) = 
0.0096; P = 0.99). 
 
3.3  Nipecotic acid 
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   The GABA transport (GAT-1) inhibitor nipecotic acid (100µM) was applied for 
10min before and during a series of applications of EDA. The concentration of 100µM 
was selected as one which had no effect alone on the fepsp size. With this protocol, 
nipecotic acid produced a gradual enhancement of the size (Fig. 3A,B,C) and 
particularly the duration of responses to EDA, with no change in the size of the 
axonal volley (Fig. 3B). The potentiation of EDA responses recovered to a level not 
significantly different from the original values (Fig. 3A,C,D) 
 
3.4  Chelation 
     EDA is well-established as a chelator of metal ions, for which property it is widely 
used in the chemical synthesis of organo-metallic complexes, it was considered that 
the depression of evoked potentials, particularly that component of the depression 
that was not prevented by bicuculline or gabazine, might reflect the chelation of Ca++ 
ions. Doubling the calcium content of the aCSF increased the size of the baseline 
fepsp by approximately 20%, but did not reduce the percentage fepsp depression 
produced by 500µM EDA (41.6 ± 3.7%, n = 4 in normal aCSF, 38.8 ± 1.7%, n = 4 in 
elevated calcium, P = 0.53) . Similarly the possibility was also considered that the 
initial increase in fepsp slope seen in some slices (see above) might result from the 
chelation of Mg++, possibly resulting in an initial overdepolarisation of slices caused 
by increased sensitivity of NMDA receptors. When a slice was encountered in which 
EDA produced a clear and reproducible initial increase of fepsp size, the selective 
NMDA receptor antagonist CPP (10µM) was superfused. However, CPP did not 
prevent either the early hyperexcitability (control increase 18.23 ± 3.6%, with CPP 
22.8 ± 3.8%, n = 3, P = 0.44) or the predominant depression of fepsp slope (control 
depression 50.9 ± 5.6%, with CPP 44.9 ± 6.3, n = 4, P = 0.51). 
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 3.5  Antidromic potentials 
    The foregoing results suggest thatsome of the depression of fepsps produced by 
EDA could be attributed to activation of GABAA receptors, but the origin of the 
occasional increase of excitability, and of that fraction of neuronal inhibition that was 
not blocked by bicuculline, remained unclear. It was therefore decided to test EDA on 
non-synaptic potentials evoked by the antidromic activation of CA1 pyramidal cells. 
Even with this paradigm, EDA at 300µM continued to depress the amplitude of the 
antidromic population spikes (Fig. 4A,B). When these slices were superfused with 
kynurenic acid, a non-selective antagonist at glutamate receptors (Perkins and 
Stone, 1982b; Stone 2001), using a concentration of 2mM, there was no significant 
change in the size of the EDA-induced depression (Fig. 4A,B).  
 
3.6  β-alanine 
     In addition to forming a GABA-like agonist complex, the structure of EDA might 
lend itself to the formation of a complex or carbamate compound similar in electronic 
structure to β-alanine, which has inhibitory activity on central neurons. Applications of 
β-alanine depressed orthodromic potentials with a potency comparable to that of 
EDA (Fig. 5A), producing a reduction in the fepsp of 83.05 ± 3.48% (n = 5) at a 
concentration of 2mM and 44.72 ± 3.94% (n = 4) at 500µM. Superfusion with 
bicuculline at 100µM did not change the depression of fepsps whereas strychnine 
(20µM) produced a selective block of the depressant response which developed 
during a strychnine application lasting 30min (Fig. 5A,B).  
     The depression of fepsps by β-alanine was preceded in most cases (7 of 8 slices 
tested using 500µM) by a significant increase in the slope of the potential (Fig. 5A). 
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This was larger, longer-lasting and appeared in a larger proportion of slices than was 
the initial increase sometimes seen with EDA. The initial increase of fepsp size was 
not reduced by superfusion with bicuculline or strychnine (Fig. 5A,C).  
 
3.7  Intracellular recordings 
     Since the foregoing results presented a complicated picture of mixed excitatory 
and inhibitory components in the response to EDA, experiments were performed to 
address further the mechanism of action of EDA by intracellular recordings using 
classical sharp electrodes. A total of 22 neurones in the CA1 pyramidal layer were 
recorded (in separate slices), with resting membrane potentials ranging from -66 to -
81mV. The application of EDA to the slices for 2min produced, in most cases (16 of 
22), and at both the 300µM or 1mM concentrations examined, a rapid depolarisation 
of the neurones (Fig. 6A).  
     The depolarisations produced by EDA at 1mM reached 27.93 ± 2.0 mV (n = 16). 
This depolarisation was associated with a marked decrease of membrane input 
resistance from baseline values of 57.9 ± 3.8 MΩ to  32.3 ± 2.5 MΩ (P = 0.0002; n = 
6)(Fig. 6A,B), the decreased resistance still being apparent when the membrane 
potential was clamped at the original resting potential (Fig. 6C). The application of 
concentrations greater than 1mM usually resulted in overdepolarisation of the 
neurones. 
     In several cases (6 of 22 cells), the depolarisation was preceded and followed by 
a marked hyperpolarisation (Fig. 6B) which reached 9.75mV  ± 2.15 in those 6 
neurons, all of which were treated with EDA at 1mM.  
     The mechanism of the EDA-induced depolarisation was probed by perfusing with 
kynurenic acid (2mM) for 10 min before, during and for 10min following EDA 
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(500µM). Kynurenic acid produced only small and non-significant changes in the size 
of the overall EDA depolarisations, which were reduced from 22.2 ± 3.6 mV to 21.1 ± 
3.9 mV (P = 0.83, n = 4).  
   Superfusion with bicuculline (20µM) reduced the amplitude of EDA depolarisations 
elicited at 1mM (Fig. 7A,B) or 300µM concentrations, an effect which reached a 
maximum plateau after about 30 min of superfusion, consistent with the effects seen 
using synaptically-evoked potentials (above). Strychnine 20µM did not change the 
magnitude of the EDA depolarisations (controls 26.6mV ± 3.6mV, with strychnine 
24.3 ± 2.9mV, n = 4, P = 0.64).  
     Applications of GABA for 2 min (1mM) generated complex responses which in 
most cases (5 of 7 cells) involved an early depolarisation which attained a peak 
within about 30secs and then declined substantially during the presence of GABA. 
These responses closely resembled in profile the changes of extracellularly recorded 
fepsps described above. The responses were fully blocked by superfusion with 
bicuculline (20µM), but not strychnine (20µM), and were unaffected by the GABAB 
receptor antagonist CGP35348 (100µM)(data not shown).  
     When applied during intracellular recording, β-alanine (1mM) produced a 
depolarisation of 22.3mV ± 3.1 (n = 4), preceded in 3 cases by an initial and 
subsequent hyperpolarisation (6.4mV ± 0.69, n = 3) very similar to those seen with 
EDA (above, Fig. 6B). Strychnine produced a gradual blockade of the depolarising 
phase of these responses (to  8.9mV ± 2.7, n = 4, P = 0.002 using paired t test), with 
no effect on the hyperpolarisations (6.0mV ± 0.67, n = 3, P = 0.72). Bicuculline 
(100µM) had no significant effect on either component of the β-alanine responses.  
 
3.8  Adipic acid 
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   Given the chemical structure of EDA, and previous evidence for its ability to form 
acidic complexes with bicarbonate ions, the possibility was considered that a similar 
di-carboxy adduct might be responsible for the bicuculline-resistant neuronal 
depolarisation. Such an adduct should most closely resemble adipic acid in structure, 
and this compound was therefore tested on slices. 
     Adipic acid itself produced little effect at 1mM, with small and inconsistent effects 
at 2mM. At a concentration of 10mM it produced changes of the fepsps which were 
either increased (22.6 ± 3.0%, n = 4, significantly different from baseline, P = 0.005), 
or decreased (21.8 ± 3.3%, n = 5, significantly different from baseline, P = 0.003). 
These effects were not only smaller than those produced by EDA (at 1mM), but were 
also slower in both onset and recovery (Fig. 8A). Intracellular recordings showed 
that, like EDA, the dominant effect of adipic acid on CA1 neurones was one of 
depolarisation with increased membrane conductance but these responses were 
unaffected by bicuculline (20µM) or strychnine (20µM) (data not shown). 
   In view of the structural similarity between EDA monocarbamate and adipic acid 
and α-amino-adipic acid (αAA), and the fact that the latter compound was one of the 
earliest antagonists to be identified at glutamate receptors (Biscoe et al., 1977), the 
possibility was considered that EDA carbamates and adipic acid might both act as 
weak NMDA receptor agonists, and might be antagonised by αAA. However, this 
was not the case, and when superfused at a concentration of 1mM, αAA had no 
significant activity against the responses to either EDA or adipic acid (Fig. 8A,B). 
 
3.9  Role of extracellular bicarbonate 
   In order to pursue the question of whether the activity of EDA was attributable to 
complex formation with bicarbonate, 25% of the normal bicarbonate content of the 
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aCSF was replaced by HEPES. This substitution reduced significantly the depression 
of evoked potentials by 1mM EDA from 75 ± 5% (n = 6) to 40 ± 5% (n = 6) (P < 
0.001), while there was no change in the depression produced by 1mM GABA 
(controls 40 ± 5%, with HEPES 40 ± 5%, n = 6, n.s.).  
 
3.10  Channel modulation 
   4,4’-di-isothiocyano-stilbene-2,2’-disulphonic acid (DIDS), a blocker of chloride / 
bicarbonate exchange, is known to block the conductance changes induced by 
GABA and hence to reduce its depolarising and hyperpolarising actions (Bonnet and 
Bingmann, 1995).  When tested against responses to EDA, DIDS (20µM) reduced 
substantially the depolarisation and depression of evoked potentials: the effect of 
1mM EDA was reduced from 70 ± 5% (n = 8) to 20 ± 5% (n = 8) (P < 0.001), 
consistent with a similar site and mechanism of action between EDA and GABA.     
 
3.11  In vivo experiments 
   In order to determine whether EDA had any effect on evoked potentials under more 
physiological conditions, the somatosensory evoked potential (SEP) was examined in 
anaesthetised rats. When applied for 5 min EDA (25mM) produced an initial short-
lasting increase in the amplitude of the negative (N) phase of the SEP (by 12 ± 7%, n 
= 5), invariably followed by a decrease (by 30 ± 12%, n = 5) (Fig. 9A,B). A higher 
concentration produced a much lower initial increase in the SEP but subsequently 
decreased it by 74 ± 5% (n = 5) (Fig 9B). EDA at 5 mM did not affect the size or 
shape of the SEPs (n = 5). 
     To examine the role of GABA-A receptors in these effects, bicuculline was also 
applied topically at a concentration of 10µM for 15 min before and during the 
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application of EDA.  This compound increased the overall amplitude of the SEP by 
77 ± 34% (n = 7)(Fig. 9C), with the greatest change occurring in the positive (P) 
phase of the potential.  However, the application of EDA (in the continued presence 
of bicuculline) still caused an immediate and complete abolition of the evoked 
positive wave and a gradual decrease in the overall amplitude of the SEP by 22 ± 
15% (n = 7). There was no significant difference in the degree of SEP depression 
caused by EDA on its own or in the presence of bicuculline (two-tailed t test; P = 
0.40). 
 
4.  DISCUSSION 
     Although several agents are available with which to explore the pharmacology 
and physiological roles of GABA receptors, uptake and metabolism, there are few 
with which to probe neuronal or behavioural responses to the selective release of 
endogenous GABA. As noted in the Introduction EDA appeared to be an efficient 
GABA-mimetic, partly by inducing GABA release and partly by direct activation of 
GABAA receptors in the CNS (Perkins and Stone, 1980, 1982a; Blaxter and 
Cottrell,1985; Bokisch et al., 1984; Lloyd et al., 1982a,b). The effects of EDA 
extended to the modulation of benzodiazepine binding (Morgan and Stone, 1982; 
Davies et al., 1982). 
     The ability of EDA to release GABA is a result of the uptake of EDA itself by a 
nipecotic acid-sensitive transporter, possibly producing an exchange with GABA 
since the GABA release is calcium-independent (Lloyd et al., 1982a,b). Here, 
nipecotic acid increased the size and duration of the EDA effects on fepsps, implying 
that the balance of nipecotic acid’s activity is to prevent re-uptake of GABA rather 
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than to reduce the initial uptake of EDA (since the EDA response would then be 
reduced). 
     The observation that EDA could produce a long-lasting depression in some slices 
could imply a modification of receptors – such as those for glutamate – involved in 
the generation of long-term depression (LTD), or could simply reflect the 
accumulation of EDA within the tissue. We consider the former explanation more 
likely given that the early time course of recovery was normal, the plateau of 
depression could be maintained for up to one hour, and that shorter (5min) 
applications of EDA appeared more likely to produce this LTD. Present experiments 
are being directed at further understanding of the mechanisms of the LTD. 
     Following the proposal that this GABA-mimetic activity might involve a complex 
formed between EDA and bicarbonate (Stone and Perkins, 1984), strong supporting 
evidence for this hypothesis was obtained by demonstrating, physiologically and 
spectroscopically, the existence of EDA monocarbamate in solutions of EDA gassed 
with 5%CO2 in oxygen (Curtis and Malik, 1984; Myers and Nelson, 1990). Ejecting 
the active monocarbamate ion onto individual neurones resulted in a larger and more 
rapid depression of firing than was seen with EDA alone. 
     However, there has been little detailed systematic or quantitative work on the 
pharmacology of EDA and the present work was designed to pursue this. The profile 
of extracellular and intracellular recordings is consistent with previous work showing 
that somatic applications of GABA and EDA generate bicuculline-sensitive 
hyperpolarisations, while dendritic applications produce bicuculline-sensitive 
depolarisations (Blaxter and Cottrell, 1985). The intracellular depolarisation 
presumably corresponds to the extracellularly recorded depression of fepsps. 
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Equally, the increase of fepsp size is most probably a result of the intracellularly 
recorded hyperpolarisation, both effects being resistant to bicuculline.  
     These results, together with the reduced responses to EDA in lowered 
extracellular bicarbonate therefore support the postulated  activation of GABA 
receptors by EDA, probably via an EDA-bicarbonate complex. Perhaps more 
importantly, the present study has revealed an additional mechanism of action of 
EDA. Structurally, EDA monocarbamate is similar not only to GABA, but also to β-
alanine (Fig. 10), and EDA can release preloaded β-alanine as well as GABA from 
neurones (Davies et al., 1983). Indeed, EDA is a more effective inhibitor of β-alanine 
uptake than of GABA uptake (Davies et al., 1982; Forster et al., 1981), possible 
suggesting that EDA may be a better inhibitor of glial transport (β-alanine) than of 
neuronal uptake (GABA) (Davies et al., 1982). 
     It is, therefore, intriguing to discover in this study that the effects of EDA are 
closely mimicked by applications of β-alanine, an amino acid recognised primarily for 
its ability to activate glycine receptors. Both EDA and β-alanine produced an initial 
increase of fepsp size preceding the reduction in their size, and both also produced 
intracellularly recorded depolarisations, often preceded by an underlying 
hyperpolarisation, with no fade being seen in the presence of the agonist. In contrast 
GABA itself was able to produce only a decrease of fepsp size and intracellular 
depolarisation, with both the extracellular and intracellular responses exhibiting 
marked fade after about several seconds of the GABA applications. However, 
despite these similarities, the effects of EDA and β-alanine remain largely distinct 
since the EDA-induced depression of fepsps and the intracellular depolarisation were 
blocked to a large extent, though not completely, by bicuculline, whereas these 
effects of β-alanine were blocked by strychnine. 
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   The simplest interpretation of these data is that while EDA, almost certainly in the 
form of its monocarbamate, is able to activate GABAA receptors, and β-alanine is 
able to activate strychnine-sensitive, conventional, glycineA receptors, there is a third 
site which is resistant to bicuculline and strychnine at which both EDA and β-alanine, 
again in the form of their monocarbamates, produce hyperpolarisation when recorded 
intracellularly, and the increased fepsp size when recorded extracellularly. This 
response would correspond to the dendritic, bicuculline-resistant, hyperpolarisation 
observed by Blaxter and Cottrell (1985) when GABA was applied locally to the 
dendritic region. It has been proposed by others, based on a substantial amount of 
evidence on uptake, release and actions, that β-alanine could function as an  
independent neurotransmitter (DeFeudis and del Rio, 1977; Sandberg and Jacobson, 
1981). 
   The activity of EDA at sites which are resistant to blockade by bicuculline was 
noted both in hippocampal slices and at the somatosensory cortical surface in vivo. 
In order to explain this bicuculline-resistant fraction of responses to EDA, two 
hypotheses were considered and tested in the slice preparation. Firstly, it is 
conceivable that EDA might form, in addition to the monocarbamate structure, a 
dicarbamate analogue which would resemble adipic acid in structure (Fig. 10). Such 
a complex might then activate classical excitatory amino acid receptors, or a distinct 
dicarboxylic acid receptor. The former possibility was tested using a high 
concentration of the general glutamate receptor antagonist kynurenic acid (Perkins 
and Stone 1982b; Stone and Darlington 2002), but this compound failed to block the 
depression of antidromically-induced potentials or the intracellularly recorded 
depolarising responses to EDA, suggesting that activation of glutamate receptors 
cannot account for the results. 
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     A role for an adipic acid receptor was also tested by applying adipic acid itself to 
the slices, where it did produce a depression of fepsps and an intracellular 
depolarisation. Those effects were not blocked by either bicuculline or strychnine, 
leaving open the possibility that EDA dicarbamate and adipic acid could act partly by 
a novel receptor site or transporter. Neither the EDA receptor nor the adipic acid site 
were blocked by α-aminoadipic acid, an antagonist at glutamate receptors (Biscoe et 
al., 1977; Stone, 1979).  
   The blockade of EDA responses by DIDS strongly supports the involvement of 
common ionic mechanisms between GABA and EDA. In addition, it may be that the 
poor blockade of EDA effects by bicuculline reflects a direct action on GABA 
receptors distal to the site of action of GABA itself, explaining the common 
dependence on chloride but with recognisably distinct pharmacology. A direct action 
of some kind is certainly needed to account for the GABA-like effects in the absence 
of synaptic terminals (Morgan and Stone, 1982; Davies et al., 1982) and such an 
action, rather than activation of sites sensitive to agents such as β-alanine or adipic 
acid, could account for many of the present results. 
   The work in vivo provides an interesting comparison with the hippocampus in vitro. 
The SEPs result from the depolarization of pyramidal cells by thalamo-cortical 
afferents. A subsequent positive wave due to the spread of depolarization to 
superficial cortical layers (I – III) is increased by the removal of tonic inhibition from 
GABAergic interneurons in these superficial layers (Addae et al. 2007; Jellema et al, 
2004; Reyes et al. 1998), confirming a role for endogenous GABA release. The 
results provide strong support to the findings in vitro. The profile of the trendplot of 
the SEPs shows an initial slight increase in the SEP size and a subsequent more 
prolonged decrease followed by recovery. The profile is similar to that seen in some 
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of the in vitro recordings (e.g. Fig 3).The in vivo profile is consistent with the report 
that depolarizing GABA responses are found in the superficial cortical layers where 
topical EDA is likely to exert its initial effect (DeFazio et al., 2005). It is clear that EDA 
is able to exert a profound inhibitory action on SEPs similar to the inhibition noted in 
vitro. Also, and perhaps more importantly, the effects of EDA are at least partially 
resistant to bicuculline, since they are not prevented by concentrations of bicuculline 
that induce an increase of neuronal excitability sufficient to double the amplitude of 
an SEP and to induce multiple PS and spontaneous epileptiform activity in the 
neocortex. Indeed, this failure of bicuculline to block the EDA effects in vivo suggests 
that the direct effects of EDA on GABA receptors or channels noted above is 
relatively more important in vivo than it is in vitro. 
    Following the initial reports concerning EDA, it became clear that an interaction 
with bicarbonate or carbon dioxide was required for the excitatory and toxic action of 
β-N-methylamino-L-alanine  (BMAA) at excitatory amino acid receptors (Myers and 
Nelson, 1990). Also, high concentrations of neutral amino acids such as L-alanine 
and L-proline, can activate glutamate receptors (Pace et al., 1992). The formation of 
carbamates or similar complexes of these amino acids in bicarbonate-containing 
media could generate molecules able to mimic glutamate, making them relevant to 
excitotoxicity in physiological or pathological conditions in which their concentrations 
are elevated. 
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Figure legends: 
 
Figure 1. Responses of hippocampal slices to EDA. 
A. illustrates the effects of EDA when applied for 10 min to allow the attainment of a 
plateau depression. Responses to three concentrations are illustrated: 100µM (n = 
5), 300µM (n = 4) and 1000µM (n = 16). B. is of field epsps from one slice showing 
the baseline potential (the largest epsp) and sample potentials recorded at the peak 
depression induced by 50, 100, 300, 500 and 1000µM EDA (progressively smaller 
epsps). The traces indicate that the depression of the epsps was not accompanied 
by any change of axonal volley. C. shows the log concentration-response curves for 
EDA (filled circles, n = 6-8) and GABA (open circles, n = 5-6). The measurements 
were based on the mean of the last 10 epsps recorded during superfusion with EDA 
or GABA for 10 min. D. shows the mean data for 4 slices in which EDA (1mM) 
produced a long-lasting depression of the fepsp. 
Calibrations for B: 0.5mV and 5ms. 
Data are shown as mean ± S.E.M.. 
 
Figure 2. Effects of bicuculline and gabazine on responses to EDA. 
A. The time course of the depression of fepsps by EDA (1000µM, n = 5) applied for 2 
min, and its partial blockade by bicuculline methobromide (BIC, 20µM, n = 4).  
B. illustrates records of epsps from a slice treated with bicuculline 100µM, showing 
the baseline potential, the depression produced by EDA 1000µM, and the partial 
blockade by bicuculline. 
C. shows the overall data in which bicuculline at 20µM (n = 5) and 100µM (n = 3) or 
gabazine at 20µM (n = 3) and 100µM (n = 3) produced a partial blockade of the 
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responses to EDA (1mM). There is no significant difference between the blockade 
produced by the two concentrations of antagonist, suggesting that the blockade is 
maximal. Strychnine at 10 or 100µM failed to modify the responses to EDA. 
Data are shown as mean ± S.E.M..  
** P < 0.01 compared with the control response to EDA (Dunnett’s test for multiple 
comparisons). 
 
Figure 3. Effects of nipecotic acid on responses to EDA. 
A. Amplitudes of the first of a series of fepsp depressions induced by EDA 300µM 
(filled circles), the increase in amplitude and duration of the response sampled as the 
maximum response to EDA in the presence of nipecotic acid 100µM (open circles), 
and recovery towards the original response profile (filled triangles). Nipecotic acid 
was applied for 15 min before, during and for 30 min following EDA. 
B. Sample traces showing the fepsps recorded (a) at baseline, (b) at the peak of 
depression produced by the first application of EDA and (c) at the peak of depression 
produced by EDA in the presence of nipecotic acid. 
C. summarises the time course of change in the mean size of the depression 
produced by EDA when slices were superfused with nipecotic acid (100µM). 
D. summarises the overall data in which nipecotic acid produced a significant 
increase in the amplitude of the EDA response. 
Data are shown as mean ± S.E.M. (n = 6). 
** P < 0.01 compared with the control response to EDA. 
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Figure 4. Effects of kynurenic acid on antidromically-evoked spikes. 
A. The depression of antidromic spike amplitude produced by EDA 1mM in the 
absence (filled circles) and presence (open circles) of kynurenic acid 2mM. 
Kynurenic acid was present for 15 min before, during and for 20 min following the 
application of EDA, but failed to modify the EDA response. 
B. Sample antidromic spikes recorded (a) at baseline, (b) at the peak depression 
produced by EDA and (c) at the peak depression produced by EDA in the presence 
of kynurenic acid.  
Data are shown as mean ± S.E.M. (n = 5). 
 
Figure 5. Effects of β-alanine on fepsps. 
A. When applied for 5min at concentrations of 500µM, β-alanine (closed circles, n = 
4) induced a depression of fepsp slope which was smaller and slower than that 
produced by EDA. Strychnine 100µM (open triangles, n = 4), applied for 15 min 
before, during and for 30 min after β-alanine reduced the size of depressant 
response but did not change the initial increase in fepsp size. 
B. illustrates sample fepsps at baseline (a), at the time of maximum inhibition by β-
alanine (b) and when blocked by strychnine (c).  
C. chart summarising the decreased fepsp size produced by β-alanine (β-ala), the 
failure of bicuculline (bic) to modify that depression, and the blockade by strychnine 
(stry), and failure of bicuculline or strychnine to modify the initial increase in fepsp 
size produced by β-alanine. 
** P < 0.01 (n = 4) compared with the control response to β-alanine alone. 
Calibrations: 1mV, 10ms. 
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Figure 6. Intracellular recordings of the effects of EDA on a CA1 pyramidal neuron.  
A. illustrates a typical record of the depolarisation produced by EDA 300µM. The 
depolarisation is associated with an increase in membrane conductance, tested 
using 500ms pulses of hyperpolarising current (downward deflections). The upward 
deflections on the trace are spontaneous epsps which are suppressed by the 
membrane depolarisation. B. illustrates both the larger depolarisation and 
conductance change produced at 1mM EDA, and an underlying hyperpolarisation 
which occurs before and following the depolarisation (6 neurons). C. illustrates a 
neuron depolarised by EDA (500µM) in which, during the period indicated by the 
hatched bar, the membrane potential was manually clamped at the resting potential 
to confirm that the decrease of membrane resistance was still observed under these 
conditions. 
Calibrations in A: 5mV and 1min; calibrations in B, C: 10mV and 1 min. 
 
Figure 7. Blockade of EDA depolarisation by bicuculline.  
A. (a) illustrates the initial depolarisation induced by EDA, 1mM, while (b) shows the 
response after the application of bicuculline methobromide (20µM, 20min). In (c) the 
response to EDA recovers substantially following removal of the antagonist. B. The 
effect of bicuculline was statistically significant, with recovery reaching an amplitude 
not significantly different from the initial value (n = 4). Calibrations in A: 20mV and 
2min. Action potentials triggered in this cell have been cut off. 
**P < 0.01 relative to EDA alone. 
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Figure 8. Responses to EDA and adipic acid. 
A. Control responses are shown (open circles) for typical responses to an application 
of EDA at 500µM followed by the smaller and slower effect of adipic acid (2mM). 
Superimposed on that plot are responses after superfusion with α-aminoadipic acid 
(1mM, closed circles). There is no effect of α-aminoadipic acid on the response to 
adipic acid, although there is a small apparent reduction in the response to EDA.  
B. The overall analysis indicated that α-aminoadipic acid had no significant effect on 
the response to EDA or adipic acid. Data are shown as mean ± S.E.M. for n = 4. 
 
Figure 9. Effects of EDA on somatosensory evoked potentials (SEPs) in vivo. 
A. A typical individual record showing a response to topical EDA (25 mM for 5 min) 
causing an initial increase and then a decrease in the SEPs. B. Graphs of the pooled 
data showing a concentration dependent effect of EDA at 25 mM (black circles) and 
50 mM (open circles) (n = 5 at each concentration). The initial increase (more 
marked at the lower concentration) was followed by the decrease which recovered 
slowly to the control level.  C. Bicuculline (10 µM for 15 min) caused an increase in 
the SEPs but did not significantly affect the decrease in the size of the SEP caused 
by EDA. Note especially the immediate and complete abolition by EDA of the 
increased positive wave caused by bicuculline. The graphs show the changes in 
amplitude of the first negative (downward) wave of the SEP with each point being an 
average of 30 SEPs recorded over 1 min. The representative waveforms represent 
individual sample SEPs taken at the times (a,b,c,d) indicated on the time graph. 
 
Figure 10 Chemical structures of relevant molecules. 
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Figure 2 
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Figure 4 
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 Figure 7 
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Figure 8 
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Figure 9 
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Figure 10 
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